The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Open accessAbstract
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“EPI-001 targets the NTD of the AR (80), whereas MDV 3100 binds to the LBD (81), similarly to bicalutamide.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ARE repeat reporter (4X-ARE, firefly luciferase) has been previously described (Tran et al., 2009).”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Tran et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,759
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citationScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationStructural basis for antagonism and resistance of bicalutamide in prostate cancer
Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500381102 · Cited by 426
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 392
Larson, S. M., Morris, M. J., Guenther, I., Beattie, B., Humm, J. L., Akhurst, T., Finn, R. D., Erdi, Y. E., Pentlow, K. S., Dyke, J., et al. (2004) · PubMed · Cited by 298
Self-citationMasiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178
Hodgson, M. C., Astapova, I. I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 143
Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Liu, W., Xie, C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S. L., Turner, A. R., Sun, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08428 · Cited by 128
Flagged first, then by citations
1 of the 21 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Larson S. M., et al.., J. Nucl. Med. 45, 366 (2004).15001675
Cited by
Sorted by citations
Items 901–1,000 of 1,000
RETRACTED: Lin28 induces resistance to anti‐androgens via promotion of AR splice variant generation
Tummala, R., Nadiminty, N., Lou, W., Evans, C. P., & Gao, A. C. (2015) · The Prostate · doi:10.1002/pros.23134 · Cited by 25
RetractedZhu, H., & Garcia, J. A. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0300-1 · Cited by 25
WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer
Leach, D. A., Powell, S. M., & Bevan, C. L. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0319 · Cited by 25
Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives
Hu, J., Wang, G., & Sun, T. (2017) · Tumor Biology · doi:10.1177/1010428317692259 · Cited by 25
Bhati, S., Kaushik, V., & Singh, J. (2018) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-018-9734-5 · Cited by 25
Shi, Q., Zhu, X., & Deng, S. (2019) · Journal of Food Science · doi:10.1111/1750-3841.14586 · Cited by 27
Udhane, V., Maranto, C., Hoang, D. T., Gu, L., Erickson, A. M., Devi, S., Talati, P. G., Banerjee, A., Iczkowski, K. A., Jacobsohn, K. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0508 · Cited by 25
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Hoefer, J., Schwaiger, S., Heidegger, I. M., Matuszczak, B., Schuster, D., et al. (2020) · Cancers · doi:10.3390/cancers12082092 · Cited by 26
Antonarakis, E. S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.999044 · Cited by 25
Castration-Resistant Prostate Cancer: Descriptive Yet Pejorative?
Crawford, E. D., & Petrylak, D. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7664 · Cited by 25
Small-molecule RNA therapeutics to target prostate cancer
Kuzuoglu-Ozturk, D., Nguyen, H. G., Xue, L., Figueredo, E., Subramanyam, V., Liu, I., Bonitto, K., Noronha, A., Dabrowska, A., Cowan, J. E., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.027 · Cited by 24
Enzalutamide for the treatment of prostate cancer
Pal, S. K., Stein, C. A., & Sartor, O. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.775251 · Cited by 24
Androgen receptor antagonists: a patent review (2008 – 2011)
Mohler, M. L., Coss, C. C., Duke, C. B., Patil, S. A., Miller, D. D., & Dalton, J. T. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.682571 · Cited by 25
Pra, A. D., Locke, J. A., Borst, G. R., Supiot, S., & Bristow, R. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00024 · Cited by 24
Courtney, K. D., & Taplin, M. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351059d · Cited by 24
Takayama, K. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0328 · Cited by 24
Wu, W. D., Tang, S., Zhang, Y., Puppala, M., Cooper, T. K., Xing, C., Jiang, C., & Lü, J. (2017) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x17500963 · Cited by 24
Dellis, A., & Papatsoris, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1548611 · Cited by 24
PlexinB1 Promotes Nuclear Translocation of the Glucocorticoid Receptor
Williamson, M. P., Garg, R., & Wells, C. M. (2019) · Cells · doi:10.3390/cells9010003 · Cited by 26
Li, Z., Sun, C. Q., Tao, S., Osunkoya, A. O., Arnold, R. S., Petros, J. A., Zu, X., & Moreno, C. S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100751 · Cited by 24
The androgen receptor messenger RNA: what do we know?
Likos, E., Bhattarai, A., Weyman, C. M., & Shukla, G. C. (2022) · RNA Biology · doi:10.1080/15476286.2022.2084839 · Cited by 28
Bone Health Management in the Continuum of Prostate Cancer Disease
Boopathi, E., Birbe, R., Shoyele, S., Den, R. B., & Thangavel, C. (2022) · Cancers · doi:10.3390/cancers14174305 · Cited by 24
Chen, J., Xu, D., Wang, T., Yang, Z., Yang, Y., He, K., & Zhao, L. (2022) · Oncology Reports · doi:10.3892/or.2022.8412 · Cited by 24
Chang, Y., Wang, X., Yang, J., Tien, J. C.-Y., Mannan, R., Cruz, G., Zhang, Y., Vo, J. N., Magnuson, B., Mahapatra, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101752 · Cited by 24
Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists
Guo, C., Pairish, M., Linton, A., Kephart, S. E., Ornelas, M. A., Nagata, A., Burke, B. J., Dong, L., Engebretsen, J., & Fanjul, A. N. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.116 · Cited by 24
New Hormonal Therapies for Castration-Resistant Prostate Cancer
Mostaghel, E. A., & Plymate, S. R. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.013 · Cited by 26
New treatment developments applied to elderly patients with advanced prostate cancer
Mukherji, D., Pezaro, C. J., Shamseddine, A. I., & Bono, J. S. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.004 · Cited by 24
Narayanan, R., Yepuru, M., Szafran, A. T., Szwarc, M. M., Bohl, C. E., Young, N. L., Miller, D. D., Mancini, M. A., & Dalton, J. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3206 · Cited by 24
Oh, S., Nam, H. J., Park, J., Baek, S. H., & Park, S. B. (2010) · ChemMedChem · doi:10.1002/cmdc.200900509 · Cited by 24
Masoodi, K. Z., Xu, Y., Dar, J. A., Eisermann, K., Pascal, L. E., Parrinello, E., Ai, J., Johnston, P. A., Nelson, J. B., Wipf, P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0176 · Cited by 24
Sakamoto, S., Maimaiti, M., Xu, M., Kamada, S., Yamada, Y., Kitoh, H., Matsumoto, H., Takeuchi, N., Higuchi, K., Uchida, H. A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040489 · Cited by 24
Non-nuclear AR Signaling in Prostate Cancer
Zamagni, A., Cortesi, M., Zanoni, M., & Tesei, A. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00651 · Cited by 26
Qin, X., Ji, D., Gu, W., Han, W., Luo, H., Du, C., Zou, Q., Sun, Z., He, C., Zhu, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02263-x · Cited by 24
Novel agents in the management of castration resistant prostate cancer
Garcia, J., & Chaturvedi, S. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.128185 · Cited by 23
Jiang, Z. K., Sato, M., Liu, W., Kao, C. H., & Wu, L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1520 · Cited by 23
Heemers, H. V., Schmidt, L. J., Kidd, E., Raclaw, K. A., Regan, K. M., & Tindall, D. J. (2010) · The Prostate · doi:10.1002/pros.21130 · Cited by 23
Tommasi, S., Pilato, B., Carella, C., Lasorella, A., Danza, K., Vallini, I., Summa, S. D., & Naglieri, E. (2018) · The Prostate · doi:10.1002/pros.23710 · Cited by 23
Drug-Drug Interactions in Prostate Cancer Treatment
Hebenstreit, D., Pichler, R., & Heidegger, I. M. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.016 · Cited by 23
Zhu, Y., & Ye, D. (2020) · Cancer Management and Research · doi:10.2147/cmar.s236879 · Cited by 23
Beinhoff, P., Sabharwal, L., Udhane, V., Maranto, C., LaViolette, P. S., Jacobsohn, K. M., Tsai, S., Iczkowski, K. A., Wang, L., Hall, W. A., et al. (2021) · Cancers · doi:10.3390/cancers13205204 · Cited by 23
Ning, S., Liu, C., Lou, W., Yang, J. C., Lombard, A. P., D'Abronzo, L. S., Batra, N., Yu, A., Leslie, A. R., Sharifi, M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0216 · Cited by 23
Prashanth, J., Drozd, K. V., Perlovich, G. L., Sridhar, B., & Surov, A. O. (2022) · Crystal Growth & Design · doi:10.1021/acs.cgd.2c00883 · Cited by 23
Joshua, A. M., Shore, N. D., Fred Saad, C., Chi, K. N., Olsson, C. A., Emmenegger, U., Scholz, M. C., Berry, W. R., Mukherjee, S. D., Winquist, E., et al. (2015) · The Prostate · doi:10.1002/pros.22965 · Cited by 23
Reddy, V., Wu, M., Ciavattone, N. G., McKenty, N. T., Menon, M., Barrack, E. R., Reddy, G. P. V., & Kim, S.-H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.671404 · Cited by 23
Copper(I) halide complexes of 2-thiohydantoin and 5,5-diphenyl-2-thiohydantoin
Aslanidis, P., Kyritsis, S., Lalia‐Kantouri, M., Wicher, B., & Gdaniec, М. (2012) · Polyhedron · doi:10.1016/j.poly.2012.08.065 · Cited by 23
Crona, D. J., & Whang, Y. E. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0193-3 · Cited by 23
Novel Therapies for the Treatment of Advanced Prostate Cancer
Clarke, J., & Armstrong, A. J. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0222-4 · Cited by 23
Androgen Receptor Modulators: A Marriage of Chemistry and Biology
McEwan, I. J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.69 · Cited by 23
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Liu, H.-H., Tsai, Y., Lai, C., Tang, C., Lai, C., Wu, H., Hsieh, J., & Yang, C.-R. (2014) · Biomedicine · doi:10.7603/s40681-014-0002-5 · Cited by 23
Levine, P. M., Lee, E., Greenfield, A., Bonneau, R., Logan, S. K., Garabedian, M. J., & Kirshenbaum, K. (2012) · ACS Chemical Biology · doi:10.1021/cb300332w · Cited by 23
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Anantharaman, A., & Friedlander, T. W. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.11.003 · Cited by 23
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Bui, C. N., O’Day, K., Flanders, S. C., Oestreicher, N., Francis, P. S. J., Posta, L. M., Popelar, B., Tang, H., & Balk, M. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.2.163 · Cited by 23
Johnson, J. K., Skoda, E. M., Zhou, J., Parrinello, E., Wang, D., O’Malley, K. J., Eyer, B. R., Kazancioğlu, M. Z., Eisermann, K., Johnston, P. A., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00186 · Cited by 23
Kato, H., Furuya, Y., Miyazawa, Y., Miyao, T., Syuto, T., NOMURA, M., Sekine, Y., Koike, H., Matsui, H., Shibata, Y., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11205 · Cited by 23
Masoodi, K. Z., Eisermann, K., Yang, Z., Dar, J. A., Pascal, L. E., Nguyen, M. C., O’Malley, K. J., Parrinello, E., Feturi, F. G., Kenefake, A. N., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00408 · Cited by 23
Shore, N. D., Heidenreich, A., & Fred Saad, C. (2017) · Urology · doi:10.1016/j.urology.2017.04.062 · Cited by 23
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide
Shatzel, J. J., Daughety, M. M., Olson, S. R., Beer, T. M., & DeLoughery, T. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022004 · Cited by 23
Self-citationOksala, R., Moilanen, A., Riikonen, R., Rummakko, P., Karjalainen, A., Passiniemi, M., Wohlfahrt, G., Taavitsainen, P., Mälmström, C., Ramela, M., et al. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.02.004 · Cited by 23
Luo, J., Tian, J., Chou, F.-J., Lin, C.-Y., Xing, E. Z., Zuo, L., Niu, Y., Yeh, S., & Chang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.025 · Cited by 23
Sequence specific suppression of androgen receptor–DNA binding in vivo by a Py-Im polyamide
Kurmis, A. A., & Dervan, P. B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz153 · Cited by 23
Joulia, M., Carton, E., Jouinot, A., Allard, M., Huillard, O., Khoudour, N., Peyromaure, M., Zerbib, M., Thomas‐Schoemann, A., Vidal, M., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.020 · Cited by 23
Miyazawa, Y., Sekine, Y., Shimizu, N., Takezawa, Y., Nakamura, T., Miyao, T., Nakayama, H., Kurihara, S., Syuto, T., Nomura, M., et al. (2019) · The Prostate · doi:10.1002/pros.23865 · Cited by 23
Coordinated AR and microRNA regulation in prostate cancer
Eringyte, I., Losada, J. N. Z., Powell, S. M., Bevan, C. L., & Fletcher, C. E. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.06.003 · Cited by 24
Structural and functional association of androgen receptor with telomeres in prostate cancer cells
Zhou, J., Richardson, M., Reddy, V., Menon, M., Barrack, E. R., Reddy, G. P., & Kim, S. (2013) · Aging · doi:10.18632/aging.100524 · Cited by 23
Kimura, G., Yonese, J., Fukagai, T., Kamba, T., Nishimura, K., Nozawa, M., Mansbach, H., Theeuwes, A. G. M., Beer, T. M., TOMBAL, B. F., et al. (2016) · International Journal of Urology · doi:10.1111/iju.13072 · Cited by 23
Self-citationA reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
Warren, A. Y., Massie, C. E., Watt, K., Luko, K., Orafidiya, F. A., Selth, L. A., Mohammed, H., Chohan, B. S., Menon, S., Baridi, A., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0501-z · Cited by 23
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
Adamo, V., Noto, L., Franchina, T., Chiofalo, G., Picciotto, M., Toscano, G., & Caristi, N. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00073 · Cited by 23
Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells
Wang, Y., Dehigaspitiya, D. C., Levine, P. M., Profit, A. A., Haugbro, M., Imberg-Kazdan, K., Logan, S. K., Kirshenbaum, K., & Garabedian, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0385 · Cited by 22
Sengupta, D., Deb, M., Kar, S., Parbin, S., Pradhan, N., & Patra, S. K. (2019) · Gene · doi:10.1016/j.gene.2019.04.046 · Cited by 22
Josefsson, A., Larsson, K., Freyhult, E., Damber, J., & Welén, K. (2019) · Cancers · doi:10.3390/cancers12010039 · Cited by 22
Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells
Samiea, A., Yoon, J. S. J., Ong, C. J., Zoubeidi, A., Chamberlain, T. C., & Mui, A. (2020) · Prostate Cancer · doi:10.1155/2020/5305306 · Cited by 22
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Lavaud, P., Dumont, C., Thibault, C., Albiges, L. K., Baciarello, G., Colomba, É., Flippot, R., Fuerea, A. C., Loriot, Y., & Fizazi, K. S. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920978134 · Cited by 23
Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
Mei, Z., Yang, T., Liu, Y., Gao, Y., Hou, Z., Zhuang, Q., He, D., Zhang, X., Tan, Q., Zhu, X., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100608 · Cited by 23
Modeling prostate cancer: What does it take to build an ideal tumor model?
Mai, C., Chin, K., Foong, L. C., Pang, K.-L., Yu, B., Shu, Y., Chen, S., Cheong, S., & Chua, C. W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215794 · Cited by 22
Triscott, J., Reist, M., KUNG, L., Mosele, F. C., Lehner, M., Gallon, J., Ravi, A., Arora, G. K., de Brot, S., Lundquist, M. R., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade8641 · Cited by 22
Jeong, S. H., Kim, H. H., Park, M. Y., Bhosale, P. B., Abusaliya, A., Won, C., Park, K., Kim, E.-H., Heo, J., Kim, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119240 · Cited by 22
Naufal, M., Hermawati, E., Syah, Y. M., Hidayat, A. T., Hidayat, I. W., & Anshori, J. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c04749 · Cited by 22
Urbanucci, A., Marttila, S., Jänne, O. A., & Visakorpi, T. (2011) · The Prostate · doi:10.1002/pros.22473 · Cited by 22
Shen, H. C., Shanmugasundaram, K., Simon, N. I., Cai, C., Wang, H., Chen, S., Balk, S. P., & Rigby, A. C. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1222 · Cited by 22
Cardiovascular toxicities of systemic treatments of prostate cancer
Veccia, A., Maines, F., Kinspergher, S., Galligioni, E., & Caffo, O. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2016.273 · Cited by 22
Kanda, T., Takahashi, K., Nakamura, M., Nakamoto, S., Wu, S., Haga, Y., Sasaki, R., Jiang, X., & Yokosuka, O. (2017) · Cancers · doi:10.3390/cancers9050043 · Cited by 22
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer
Leone, G., Tucci, M., Buttigliero, C., Zichi, C., Pignataro, D., Bironzo, P., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0355 · Cited by 22
Gupta, S., Nordquist, L. T., Fleming, M. T., Berry, W. R., Zhang, J., Ervin, S. L., Eisner, J. R., Baskin-Bey, E. S., & Shore, N. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0564 · Cited by 22
Esther, J., Maughan, B. L., Anderson, N., Agarwal, N., & Hahn, A. W. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0611-z · Cited by 22
Hashimoto, K., Tabata, H., Shindo, T., Tanaka, T., Hashimoto, J., Inoue, R., Muranaka, T., Hotta, H., Yanase, M., Kunishima, Y., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.04.026 · Cited by 22
Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75
Hu, W., Xu, L., Chen, B., Ou, S., Muzzarelli, K. M., Hu, D., Li, Y., Yang, Z., Griend, D. J. V., Prins, G. S., et al. (2019) · The Prostate · doi:10.1002/pros.23832 · Cited by 22
Wu, X., Shen, H., Zhang, Y., Wang, C., Li, Q., Zhang, C., Zhuang, X., Li, C., Shi, Y., Xing, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00763 · Cited by 22
Prostate cancer—from steroid transformations to clinical translation
Chang, K., & Sharifi, N. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.175 · Cited by 22
Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate.
Alaiya, A. A., Fox, J., Bobis, S., Matic, G., Shinwari, Z., Barhoush, E., Márquez, M., Nilsson, S. F., & Holmberg, A. (2014) · PubMed · Cited by 22
An imaging agent to detect androgen receptor and its active splice variants in prostate cancer
Imamura, Y., Tien, A. H., Pan, J., Leung, J. K., Banuelos, C. A., Jian, K., Wang, J., Mawji, N. R., Fernandez, F., Lin, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87850 · Cited by 22
Ivachtchenko, A. V., Ivanenkov, Y. A., Mitkin, O. D., Vorobiev, A. A., Kuznetsova, I. V., Shevkun, N. A., Koryakova, A. G., Karapetian, R. N., Trifelenkov, A. S., Kravchenko, D. V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.039 · Cited by 22
Guo, H., Wang, J.-J., Xiong, Y., & Wu, X. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202409605 · Cited by 21
Karbasi, A. B., Barfuss, J. D., Morgan, T. C., Collins, D., Costenbader, D. A., Dennis, D. G., Hinman, A., Ko, K., Messina, C., Nguyen, K. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52793-6 · Cited by 21
Modelling the tumor microenvironment in vitro in prostate cancer: current and future perspectives
Yuan, K., Du, X., Dong, L., Pan, J., & Xue, W. (2024) · Open Research (University of Surrey) · doi:10.1002/viw.20240074 · Cited by 21
Fujimoto, N. (2016) · Journal of UOEH · doi:10.7888/juoeh.38.129 · Cited by 21
Izumi, K., Mizokami, A., Namiki, M., Inoue, S., Tanaka, N., Yoshio, Y., Ishibashi, K., Kamiyama, M., Kawai, N., Enokida, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3661-2 · Cited by 21
Mullapudi, S. T., Helker, C. S., Boezio, G. L. M., Maischein, H., Sokòl, A. M., Graumann, J., (5992991), S. G., Matsuda, H., Kubicek, S., Yang, Y. H. C., et al. (2018) · eLife · doi:10.7554/elife.42209 · Cited by 21
Veach, D. R., Storey, C. M., Lückerath, K., Braun, K., von Bodman, C., Lamminmäki, U., Kalidindi, T. M., Strand, S., Strand, J., Altai, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3614 · Cited by 21
Self-citationFurlan, T., Kirchmair, A., Sampson, N., Puhr, M., Gruber, M., Trajanoski, Z., Santer, F. R., Parson, W., Handle, F., & Čulig, Z. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.017 · Cited by 24
Maylin, Z. R., Nicolescu, R. C. B., Pandha, H., & Asim, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101115 · Cited by 22
Metadata
- Authors
- Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Oregon Health & Science University (US)
- Medivation, Inc. (United States) (US)
- Corresponding author
- Tran, Chris
- Ouk, Samedy
- Chen, Charlie Degui
- Jung, Michael E.
- Sawyers, Charles L.
- ORCID
- Venue
- Science
- Published
- 2009-05-08
- Volume
- 324
- Issue
- 5928
- Pages
- 787-790
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2981508
- OpenAlex
- W2119504728
- Cited by
- 2,292
- References
- 21
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 110 · 2023: 141 · 2022: 139 · 2021: 150 · 2020: 152 · 2019: 131 · 2018: 146 · 2017: 145 · 2016: 157 · 2015: 134 · 2014: 163 · 2013: 163 · 2012: 160
- FWCI
- 116.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA092629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- castration-resistant prostate cancer, androgen receptor antagonists, enzalutamide, androgen receptor, bicalutamide, nonsteroidal antiandrogens, androgen receptor nuclear translocation, coactivator recruitment, prostate-specific antigen, oral anticancer drugs, drug development
- MeSH terms
- Androgen Antagonists, Anilides, Animals, Antineoplastic Agents, Benzamides, Biological Availability, Cell Nucleus, DNA, Drug Screening Assays, Antitumor, Humans, Male, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Receptors, Androgen, Tosyl Compounds, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
